FDA approves garetosmab for fibrodysplasia ossificans progressiva

The Food and Drug Administration has approved garetosmab, an antibody for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease in which soft tissue turns to bone. The approval was recorded in Drugs@FDA on 19 August 2026 under biologics licence application 761508, held by Regeneron [s2]. The drug is marketed as Pasatru [s1].

FOP is caused by a mutation in the ACVR1 gene that leaves the activin signalling pathway stuck in the "on" position, so that muscle, tendon and ligament progressively ossify into a second, disabling skeleton. Garetosmab is an antibody that blocks activin A, the protein that drives that misfiring pathway; the label describes it as an activin signalling inhibitor "indicated to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with" FOP [s1]. It is given as a 10 mg/kg intravenous infusion over 60 minutes once every four weeks, with an option to drop to 3 mg/kg if the higher dose is not tolerated [s1].

What the trial did

Approval rests on a single randomised, double-blind, placebo-controlled trial, listed in the label as Study 1 (NCT05394116), in 63 adults whose FOP was confirmed by an ACVR1 mutation [s1]. Patients were assigned to garetosmab 10 mg/kg (23 people), garetosmab 3 mg/kg (19 people) or placebo (21 people), infused every four weeks for 56 weeks [s1]. Their median age was 25 years, 60% were women, and 95% carried the classic R206H mutation [s1].

The main measure was the number of new heterotopic ossification lesions at week 56, counted on low-dose whole-body CT scans [s1]. Clinician-assessed flare-ups — the painful swelling episodes that often precede new bone — were a key secondary measure [s1].

What it found

New bone lesions fell sharply. There were 19 new lesions in 5 of 21 (24%) placebo patients, against just 2 lesions in 2 of 23 (9%) patients on 10 mg/kg and 1 lesion in 1 of 19 (5%) on 3 mg/kg [s1]. That works out to a 90% reduction at the higher dose and a 94% reduction at the lower, with rate ratios versus placebo of 0.10 (95% CI 0.01-0.76) and 0.06 (0-0.73) respectively [s1]. Flare-ups told a similar story: 9 flare-ups on 10 mg/kg and 53 on 3 mg/kg, against 66 on placebo, giving a flare rate ratio of 0.12 (95% CI 0.03-0.42) at the higher dose [s1].

Not everything the trial measured reached significance. The total volume of new bone dropped from a mean of 10.5 cm³ on placebo to near zero on both doses, but that difference did not clear the trial's prespecified statistical test [s1]. Patient-reported flare-ups also did not differ significantly between groups [s1].

The safety trade-off

Garetosmab carries real risks that shape how it can be used. The label warns that it can cause fetal harm and is contraindicated in pregnancy, so pregnancy must be excluded before treatment [s1]. That contraindication rests on animal reproduction studies in which garetosmab given to pregnant monkeys caused embryo-fetal toxicity, infant deaths and malformations after birth [s1]. It also flags skin and soft-tissue infections and spontaneous nosebleeds, including serious cases needing medical intervention [s1]. The most common adverse reactions, each in at least 10% of treated patients, were abscess, acne, increased hair growth, loss of eyelashes or eyebrows, mouth ulcers and nosebleeds [s1].

How to read it

The efficacy signal on the primary endpoint is large and consistent across both doses, which is notable in a disease where a single new episode of ossification can permanently freeze a joint. But this is one 63-patient trial in an ultra-rare condition, the bone-volume endpoint fell short of significance, and the safety list is not trivial [s1]. The counterintuitive finding that the lower 3 mg/kg dose matched or beat the higher one on lesion counts is a reminder of how much uncertainty remains at these small sample sizes [s1].

What to watch

The open questions are durability and the full risk picture over years rather than one year, and how clinicians weigh the infection and bleeding signals against a disease that is otherwise relentless [s1]. Long-term extension data will matter more here than in most approvals.

This article describes regulatory and research news and is not medical advice. Decisions about FOP treatment are for patients and their treating clinicians.

Sources

• PASATRU (garetosmab-grts) injection, prescribing information — U.S. Food and Drug Administration, label effective 14 August 2026
• Drugs@FDA: Pasatru (garetosmab-grts), BLA 761508 — approval record — U.S. Food and Drug Administration, approved 19 August 2026